165 related articles for article (PubMed ID: 18271038)
1. Novel biodegradable blend matrices for controlled drug release.
Lin M; Meng S; Zhong W; Li Z; Du Q; Tomasik P
J Pharm Sci; 2008 Oct; 97(10):4240-8. PubMed ID: 18271038
[TBL] [Abstract][Full Text] [Related]
2. A poly(ε-caprolactone) device for sustained release of an anti-glaucoma drug.
Natu MV; Gaspar MN; Ribeiro CA; Correia IJ; Silva D; de Sousa HC; Gil MH
Biomed Mater; 2011 Apr; 6(2):025003. PubMed ID: 21293056
[TBL] [Abstract][Full Text] [Related]
3. Regulation of biodegradability and drug release behavior of aliphatic polyesters by blending.
Shen Y; Sun W; Zhu KJ; Shen Z
J Biomed Mater Res; 2000 Jun; 50(4):528-35. PubMed ID: 10756311
[TBL] [Abstract][Full Text] [Related]
4. Blends of poly-(epsilon-caprolactone) and polysaccharides in tissue engineering applications.
Ciardelli G; Chiono V; Vozzi G; Pracella M; Ahluwalia A; Barbani N; Cristallini C; Giusti P
Biomacromolecules; 2005; 6(4):1961-76. PubMed ID: 16004434
[TBL] [Abstract][Full Text] [Related]
5. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
Li L; Areson C; van der Straten A; Johnson LM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
[TBL] [Abstract][Full Text] [Related]
6. Controlled protein release from electrospun biodegradable fiber mesh composed of poly(epsilon-caprolactone) and poly(ethylene oxide).
Kim TG; Lee DS; Park TG
Int J Pharm; 2007 Jun; 338(1-2):276-83. PubMed ID: 17321084
[TBL] [Abstract][Full Text] [Related]
7. Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers: Data analysis and modelling.
Siafaka PI; Barmpalexis P; Lazaridou M; Papageorgiou GZ; Koutris E; Karavas E; Kostoglou M; Bikiaris DN
Eur J Pharm Biopharm; 2015 Aug; 94():473-84. PubMed ID: 26159838
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone-loaded poly(epsilon-caprolactone) intravitreal implants: a pilot study.
Fialho SL; Behar-Cohen F; Silva-Cunha A
Eur J Pharm Biopharm; 2008 Mar; 68(3):637-46. PubMed ID: 17851057
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins.
Huatan H; Collett JH; Attwood D; Booth C
Biomaterials; 1995 Nov; 16(17):1297-303. PubMed ID: 8573667
[TBL] [Abstract][Full Text] [Related]
10. Ibuprofen-loaded poly(epsilon-caprolactone) layered silicate nanocomposites prepared by hot melt extrusion.
Campbell KT; Craig DQ; McNally T
J Mater Sci Mater Med; 2010 Aug; 21(8):2307-16. PubMed ID: 20033261
[TBL] [Abstract][Full Text] [Related]
11. Control on molecular weight reduction of poly(ε-caprolactone) during melt spinning--a way to produce high strength biodegradable fibers.
Pal J; Kankariya N; Sanwaria S; Nandan B; Srivastava RK
Mater Sci Eng C Mater Biol Appl; 2013 Oct; 33(7):4213-20. PubMed ID: 23910335
[TBL] [Abstract][Full Text] [Related]
12. Adjustable degradation and drug release of a thermosensitive hydrogel based on a pendant cyclic ether modified poly(ε-caprolactone) and poly(ethylene glycol)co-polymer.
Wang W; Deng L; Liu S; Li X; Zhao X; Hu R; Zhang J; Han H; Dong A
Acta Biomater; 2012 Nov; 8(11):3963-73. PubMed ID: 22835677
[TBL] [Abstract][Full Text] [Related]
13. Hot melt poly-ε-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin.
Puga AM; Rey-Rico A; Magariños B; Alvarez-Lorenzo C; Concheiro A
Acta Biomater; 2012 Apr; 8(4):1507-18. PubMed ID: 22251935
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-polycaprolactone blend sponges for management of chronic osteomyelitis: A preliminary characterization and in vitro evaluation.
Pawar V; Srivastava R
Int J Pharm; 2019 Sep; 568():118553. PubMed ID: 31344444
[TBL] [Abstract][Full Text] [Related]
15. Investigation of PLLA/PCL blends and paclitaxel release profiles.
Can E; Udenir G; Kanneci AI; Kose G; Bucak S
AAPS PharmSciTech; 2011 Dec; 12(4):1442-53. PubMed ID: 22038476
[TBL] [Abstract][Full Text] [Related]
16. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(epsilon-caprolactone) blends for tissue engineering applications in the form of hollow fibers.
Chiono V; Ciardelli G; Vozzi G; Sotgiu MG; Vinci B; Domenici C; Giusti P
J Biomed Mater Res A; 2008 Jun; 85(4):938-53. PubMed ID: 17896770
[TBL] [Abstract][Full Text] [Related]
17. Effects of crystalline microstructure on drug release behavior of poly(epsilon-caprolactone) microspheres.
Jeong JC; Lee J; Cho K
J Control Release; 2003 Oct; 92(3):249-58. PubMed ID: 14568406
[TBL] [Abstract][Full Text] [Related]
18. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.
Erdemli Ö; Özen S; Keskin D; Usanmaz A; Batu ED; Atilla B; Tezcaner A
J Biomater Appl; 2014 Oct; 29(4):524-42. PubMed ID: 24854983
[TBL] [Abstract][Full Text] [Related]
20.
Conde G; de Carvalho JRG; Dias PDP; Moranza HG; Montanhim GL; Ribeiro JO; Chinelatto MA; Moraes PC; Taboga SR; Bertolo PHL; Gonçalves Funnicelli MI; Pinheiro DG; Ferraz GC
Biomed Phys Eng Express; 2021 Mar; 7(3):. PubMed ID: 33652429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
